Response to reviewer 3

We thank the reviewer for these comments. We are pleased to see that our main findings have been so clearly understood. Please see our response to the individual comments below in red text.

Comments and Suggestions for Authors

Overall the authors perform the circulating tumor (ct) DNA analysis to select patients for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy CRS-HIPE for colorectal cancer patients with peritoneal metastases (PMs). Author have incorporated a NGS-based mutation analysis and droplet digital (dd)PCR method to detect mutation from PMs and (cf)DNA. cfDNA samples from 33% of patients are associated with a reduced disease-free survival (DFS) after CRS-HIPEC.

Very nice manuscript, these results indicated that ctDNA can serve as a marker for recurrence in patients with PMs of colorectal cancer.

1. Nevertheless, the authors should elaborate all the methods they have used in the method section.

We have added extra information to the materials and methods section where appropriate (lines 124-125, 135-136, 142-143). We direct the reviewer to the supplementary materials and methods for extra detail.

2. Also, check the spelling in the text, there are many mistakes.

We thank the reviewer for their careful attention to detail. We have corrected several spelling mistakes throughout the text.